|
Oct 2
|
Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Societ...
|
|
Sep 23
|
Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium
|
|
Jul 25
|
Biotech Stock Laboratory: Try a Small Experiment With Kazia Therapeutics
|
|
Jun 27
|
KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER
|
|
May 2
|
Kazia concludes first stage of Phase I advanced cancer treatment trial
|
|
May 1
|
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS
|
|
Mar 24
|
11 Best ASX Stocks To Buy Now
|
|
Mar 21
|
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
|
|
Mar 13
|
Kazia announces presentation of new data at AACR Annual Meeting
|
|
Dec 5
|
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
|
|
Dec 1
|
Kazia Therapeutics Announces $2 Million Registered Direct Offering
|
|
Nov 29
|
KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY
|
|
Jul 4
|
Insider Stock Buying Reaches AU$1.1m On Kazia Therapeutics
|
|
May 25
|
KAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOT
|